VSIR and breast carcinoma: In addition, two VISTA antagonists, JNJ-61610588 and CA-170 are currently under evaluation in clinical trials71, suggesting the necessity of elucidating the role of VISTA in ESR1 mutant breast cancer using comprehensive immune competent models.